文献速递泌尿生殖腹部MR

PI-RADS 3类病变对MRI检测前列腺癌诊断准确性的影响及各PI-RADS类别中前列腺癌的患病率:系统综述与荟萃分析

Impact of PI-RADS Category 3 lesions on the diagnostic accuracy of MRI for detecting prostate cancer and the prevalence of prostate cancer within each PI-RADS category: A systematic review and meta-analysis.
PubMed 文献 · Br J Radiol · 2020-10-22

该系统综述与荟萃分析纳入26项研究共12,913例患者(4,853例前列腺癌),评估PI-RADS 3类病变对MRI诊断准确性的影响,并估算各PI-RADS类别中临床显著前列腺癌的患病率。将PI-RADS 3类视为阳性、阴性或排除时,敏感度分别为96%、82%和95%,特异度分别为33%、71%和52%;PI-RADS 1至5类的临床显著前列腺癌患病率分别为5.9%、11.4%、24.9%、55.7%和81.4%。结论认为PI-RADS 3类病变可显著影响MRI检测前列腺癌的诊断准确性,PI-RADS 1和2类中临床显著前列腺癌患病率低。

要点

  • PI-RADS 3类病变纳入或排除会显著改变MRI检测前列腺癌的敏感度与特异度。
  • PI-RADS 1至5类的临床显著前列腺癌患病率依次为5.9%、11.4%、24.9%、55.7%、81.4%。
  • PI-RADS 3类作为阳性时敏感度96%、特异度33%,作为阴性时敏感度82%、特异度71%。

核心结论

  • PI-RADS 3类病变可显著影响MRI检测前列腺癌的诊断准确性。
  • PI-RADS 1类和2类病例中临床显著前列腺癌患病率低。
  • 将PI-RADS 3类病变纳入或排除会影响MRI检测前列腺癌的诊断准确性。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE和Embase至2020年4月10日,纳入报告按PI-RADS类别分析MRI诊断准确性的研究。
  • 共纳入26项研究、12,913例患者,其中4,853例为前列腺癌。
  • 采用双变量随机效应荟萃分析计算诊断准确性指标,PI-RADS 3类病变分别按阳性、阴性和排除三种方式处理。
  • 采用荟萃回归评估诊断准确性的差异,采用比例荟萃分析估算各PI-RADS类别中前列腺癌患病率。

诊断标准与关键数值

  • PI-RADS 3类作为阳性时,前列腺癌敏感度96%(95%CI 92-98),特异度33%(95%CI 23-44)。
  • PI-RADS 3类作为阴性时,前列腺癌敏感度82%(95%CI 75-87),特异度71%(95%CI 62-79)。
  • PI-RADS 3类排除时,前列腺癌敏感度95%(95%CI 91-97),特异度52%(95%CI 37-66)。
  • 荟萃回归显示阳性组较阴性组敏感度更高(p < 0.001)、特异度更低(p < 0.001)。
  • 临床显著前列腺癌患病率:PI-RADS 1类5.9%(95%CI 0-17.1)、2类11.4%(95%CI 6.5-17.3)、3类24.9%(95%CI 18.4-32.0)、4类55.7%(95%CI 47.8-63.5)、5类81.4%(95%CI 75.9-86.4)。

临床应用与阅片要点

  • PI-RADS 3类病变的处理方式(阳性、阴性或排除)会显著改变MRI检测前列腺癌的敏感度与特异度,阅片和报告时需明确其归类。
  • PI-RADS 1类和2类中临床显著前列腺癌患病率低(分别为5.9%和11.4%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate Prostate Imaging Reporting and Data System (PI-RADS) category 3 lesions' impact on the diagnostic test accuracy (DTA) of MRI for prostate cancer (PC) and to derive the prevalence of PC within each PI-RADS category.

METHODS: MEDLINE and Embase were searched until April 10, 2020 for studies reporting on the DTA of MRI by PI-RADS category. Accuracy metrics were calculated using a bivariate random-effects meta-analysis with PI-RADS three lesions treated as a positive test, negative test, and excluded from the analysis. Differences in DTA were assessed utilizing meta-regression. PC prevalence within each PI-RADS category was estimated with a proportional meta-analysis.

RESULTS: In total, 26 studies reporting on 12,913 patients (4,853 with PC) were included. Sensitivities for PC in the positive, negative, and excluded test groups were 96% (95% confidence interval [CI] 92-98), 82% (CI 75-87), and 95% (CI 91-97), respectively. Specificities for the positive, negative, and excluded test groups were 33% (CI 23-44), 71% (CI 62-79), and 52% (CI 37-66), respectively. Meta-regression demonstrated higher sensitivity (p < 0.001) and lower specificity (p < 0.001) in the positive test group compared to the negative group. Clinically significant PC prevalences were 5.9% (CI 0-17.1), 11.4% (CI 6.5-17.3), 24.9% (CI 18.4-32.0), 55.7% (CI 47.8-63.5), and 81.4% (CI 75.9-86.4) for PI-RADS categories 1, 2, 3, 4 and 5, respectively.

CONCLUSION: PI-RADS category 3 lesions can significantly impact the DTA of MRI for PC detection. A low prevalence of clinically significant PC is noted in PI-RADS category 1 and 2 cases.

ADVANCES IN KNOWLEDGE: Inclusion or exclusion of PI-RADS category 3 lesions impacts the DTA of MRI for PC detection.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Wadera A, Alabousi M, Pozdnyakov A, et al. Impact of PI-RADS Category 3 lesions on the diagnostic accuracy of MRI for detecting prostate cancer and the prevalence of prostate cancer within each PI-RADS category: A systematic review and meta-analysis. Br J Radiol. 2020. PMID: 33002371. doi:10.1259/bjr.20191050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。